Idorsia Advances Sleep Science with New Daridorexant Data at Sleep Europe 2024

Idorsia Ltd, based in Allschwil, Switzerland, has announced that it will present new data and analyses on daridorexant, its dual orexin receptor antagonist for treating chronic insomnia in adults, at the Sleep Europe 2024 conference. This event, the 27th Congress of the European Sleep Research Society (ESRS), will be held in Seville, Spain, from September 24 to 27, 2024.

Several research posters featuring daridorexant will be showcased during the congress. The presentations include a wide range of studies:

1. **Efficacy and Safety in Chronic Insomnia and Comorbid Nocturia**: Lederer K, et al. will present findings on the effectiveness and safety of daridorexant in patients with chronic insomnia and comorbid nocturia. This will be displayed on Wednesday, September 25.

2. **Dose-Response Meta-Analysis**: McCall WV, et al. will discuss a meta-analysis of Phase 2 and 3 studies to evaluate the dose-response relationship of daridorexant in insomnia treatment on the same day.

3. **Effect on Wakefulness and Morning Sleepiness**: Dauvilliers Y, et al. will present data on daridorexant's impact on wakefulness through the night and morning sleepiness in insomnia patients on Friday, September 27.

4. **Impact on Severe Obstructive Sleep Apnea**: Boof M-L, et al. will explore the effect of repeated 50 mg doses of daridorexant on sleep-disordered breathing and sleep in patients with severe obstructive sleep apnea, also on Friday.

5. **Nighttime Safety and Other Effects**: Muehlan C, et al. will present research on the nighttime safety of daridorexant, focusing on responses to noise stimuli and effects on postural stability, walking, and memory on Friday.

6. **Excretion into Breast Milk**: Kaufmann P, et al. will discuss the excretion of daridorexant into breast milk among healthy lactating women, with their presentation scheduled for Friday.

7. **Sleep Micro-Architecture**: Di Marco T, et al. will provide a post-hoc analysis of the effects of daridorexant on sleep micro-architecture in adults with insomnia, based on two pooled Phase 3 studies, also on Friday.

8. **Comorbid Insomnia and Mild Obstructive Sleep Apnea**: Lettieri CJ, et al. will examine the effects of daridorexant on patients with comorbid insomnia and untreated mild obstructive sleep apnea through a post-hoc analysis of a Phase 3 study, again on Friday.

The abstracts for these studies are available on the conference's website.

Additionally, Idorsia is sponsoring a satellite symposium titled "Overactive wake-signaling and the management of insomnia disorder" on Thursday, September 26. The symposium, held from 12:15 to 13:15 CEST in Room “Paris 2,” will be hosted by experts Diego Garcia-Borreguero (Spain), Yves Dauvilliers (France), Laura Palagini (Italy), and Christina Lang (Germany). They will discuss the latest standards of care for chronic insomnia patients.

**About Daridorexant**
Daridorexant is a dual orexin receptor antagonist (DORA) that inhibits the binding of wake-promoting orexin neuropeptides. Unlike drugs that induce sleep through broad inhibition of brain activity, daridorexant specifically blocks orexin receptor activation, reducing overactive wake signaling and allowing sleep to occur naturally. It works throughout the night without changing the proportion of sleep stages. Commercially known as QUVIVIQ, daridorexant is available in the US, Germany, Italy, Switzerland, Spain, the UK, Canada, Austria, and France. It is also approved throughout the EU and in Hong Kong.

**About Idorsia**
Idorsia Ltd aims to become a leading biopharmaceutical company, focusing on the discovery, development, and commercialization of small molecules to provide innovative therapeutic options. Headquartered near Basel, Switzerland, Idorsia operates in Europe and North America, leveraging a 25-year heritage of drug discovery and a broad portfolio of innovative drugs. The company has a skilled team of over 750 specialists committed to achieving its ambitious goals. Idorsia has been listed on the SIX Swiss Exchange under the ticker symbol IDIA since June 2017.